Skip to main content

Table 3 Hazard ratios (HRs) of all-cause mortality and mortality due to expanded and non-expanded CVD-related causes according to clinical stage of time-dependent annual mean eGFR stratified by proteinuria status (n=6,523)

From: Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: The Taichung Diabetes Study

  HR (95% CI)
  Without proteinuria (n=4,266) Proteinuria (N=2,257)
Variables n All-cause mortality Expanded CVD-related mortality Non-expanded CVD-related mortality n All-cause mortality Expanded CVD-related mortality Non-expanded CVD-related mortality
Age-adjusted         
Annual mean eGFR (mL/min/1.73m2)       
 ≥90 2787 - - - 899 -   
 60~89 1225 1.02 (0.75-1.39) 1.16 (0.72-1.86) 0.93 (0.62-1.40) 756 1.42 (1.03-1.96)* 1.62 (0.97-2.71) 1.31 (0.86-2.00)
 15~59 254 2.22 (1.56-3.18)*** 2.20 (1.26-3.83)** 2.28 (1.43-3.63)*** 602 2.51 (1.86-3.39)*** 3.36 (2.11-5.37)*** 1.99 (1.34-2.96)***
P for trend   <0.001 0.01 0.009   <0.001 <0.001 <0.001
Multivariate-adjusted1        
Annual mean eGFR (mL/min/1.73m2)       
 ≥90 2787 - - - 899 -   
 60~89 1225 1.13 (0.82-1.54) 1.33 (0.82-2.16) 1.00 (0.66-1.52) 756 1.56 (1.12-2.16)** 1.76 (1.05-2.95)* 1.45 (0.94-2.22)
 15~59 254 2.46 (1.69-3.57)*** 2.62 (1.47-4.70)** 2.39 (1.46-3.89)*** 602 2.58 (1.90-3.51)*** 3.28 (2.04-5.29)*** 2.14 (1.42-3.22)***
P for trend   <0.001 0.003 0.005   <0.001 <0.001 <0.001
Multivariate-adjusted2        
Annual mean eGFR (mL/min/1.73m2)       
 ≥90 2787 - - - 899 - - -
 60~89 1225 1.11 (0.81-1.52) 1.28 (0.79-2.08) 1.01 (0.67-1.53) 756 1.53 (1.10-2.12)* 1.70 (1.02-2.86)* 1.43 (0.94-2.20)
 15~59 254 2.23 (1.51-3.30)*** 1.98 (1.06-3.69)* 2.47 (1.49-4.10)*** 602 2.49 (1.83-3.39)*** 3.15 (1.96-5.09)*** 2.06(1.37-3.12)***
P for trend   <0.001 0.04 0.006   <0.001 <0.001 <0.001
  1. Multivariate-adjusted1 age, duration of diabetes, smoking, alcohol drinking, exercising, hypertension, hypertension drug treatment, obesity, hyperlipidemia and type of DM treatment and HbA1C. Multivariate-adjusted2 DKA, HHNK, severe hypoglycemia, stroke, myocardial infarction, peripheral neuropathy, intermittent claudication and neuropathy in addition to variables in model 1.
  2. *:p<0.05; **:p<0.01; ***:p<0.001.